Mithra Pharmaceuticals SA Sustainability Profile
Mithra Pharmaceuticals SA, a leading biopharmaceutical company headquartered in Belgium, is renowned for its innovative approach to women's health. Founded in 1999, Mithra has established a strong presence in Europe and beyond, focusing on the development of contraceptive solutions and hormone therapies. The company’s flagship products, including the unique contraceptive pill Estelle and the innovative hormone replacement therapy, are designed to meet the specific needs of women, setting Mithra apart in a competitive market. With a commitment to research and development, Mithra has achieved significant milestones, positioning itself as a key player in the women's health sector. Recognised for its dedication to quality and innovation, Mithra Pharmaceuticals continues to expand its portfolio, striving to improve the lives of women globally through effective and safe healthcare solutions.
DitchCarbon Score
How does Mithra Pharmaceuticals SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mithra Pharmaceuticals SA's score of 28 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mithra Pharmaceuticals SA's reported carbon emissions
Mithra Pharmaceuticals SA, headquartered in Belgium, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available from the company. As of now, Mithra Pharmaceuticals SA does not inherit emissions data from any parent or related organizations, meaning all information is self-reported and reflects their current status in climate commitments. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to broader climate goals. In the context of the pharmaceutical industry, companies are increasingly expected to set ambitious climate targets and report on their emissions transparently. However, Mithra Pharmaceuticals SA has yet to establish or communicate any such commitments.
How Carbon Intensive is Mithra Pharmaceuticals SA's Industry?
How Carbon Intensive is Mithra Pharmaceuticals SA's Location?
Mithra Pharmaceuticals SA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mithra Pharmaceuticals SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
